DILIsym® is Quantitative systems toxicology (QST) software for modeling drug-induced liver injury (DILI). Learn about the latest updates in version 8A.
Learn about the new features in industry’s only in vitro dissolution software for formulation and analytical scientists.
PBPK modeling & simulation package – supporting internal research through regulatory interactions.
The RENAsym Consortium will unite the world’s leading biopharmaceutical companies within a pre-competitive arena to collaborate, share ideas, and guide the development of a novel QST platform for predicting and understanding drug-induced kidney injury, RENAsym™.
To improve the productivity of science-based research & development enterprises by delivering innovative modeling and simulation software and insightful consulting services.
Ensuring the safety of drug therapies by leveraging our expertise in the areas of drug-induced liver injury, metabolic diseases, and modeling and simulation.
Providing strategic pharmacology and pharmacometric consulting services, PK/PD model development with NONMEM, clinical trial simulations, exposure-response evaluations, dose justification strategies and related data management services.
While our focus for the solutions we provide was initially targeted for pharmaceutical research & development, we have earned a sound reputation in other markets as we develop stronger relationships with regulatory agencies like the U.S. FDA, U.S. EPA, EMA, PMDA, ECHA, and more.
Stay up-to-date with our upcoming conference attendance & presentations, application webinars, and training workshop courses.
Find out how your peers are applying our technology by reviewing journal articles describing various user case studies.